Cheng T.-Y.Hsiao C.-H.CHIA-YU CHU2019-12-042019-12-0420081027-8117https://www.scopus.com/inward/record.uri?eid=2-s2.0-45549093471&partnerID=40&md5=ea0bd9a05485720cd210c18644806e9ehttps://scholars.lib.ntu.edu.tw/handle/123456789/434958The progression of immunosuppression-associated type Kaposi's sarcoma (KS) is thought to be related to the immunocompromised status. We herein describe a case, who had a quiescent initial lesion of KS developed in the sixth month after receiving immunosuppressive therapy for treating the refractory bullous pemphigoid. The activity of KS increased abruptly during a period of lymphocytopenia. Subsequent analysis showed CD4+ lymphocytopenia and negative anti-HIV antibody. While the dosage of corticosteroid was tapered, intralesional interferon-α2b injection was given as adjuvant therapy. The injected lesions gradually became less painful with obvious necrotic appearance. Cryotherapy and fractional radiotherapy were administered additionally and on the sixth-month of follow-up, it was observed that the majority of KS lesions had regressed.Bullous pemphigoid; Interferone-α2b; Kaposi's sarcoma; Lymphocytopenia[SDGs]SDG3amoxicillin plus clavulanic acid; azithromycin; cefepime; clobetasol propionate; corticosteroid; fluconazole; Human immunodeficiency virus antibody; immunoglobulin; interferon alpha2b; lamivudine; methylprednisolone; nystatin; piperacillin plus tazobactam; prednisolone; adult; article; bullous pemphigoid; cancer adjuvant therapy; cancer radiotherapy; case report; CD4+ T lymphocyte; cryotherapy; drug dose increase; drug dose reduction; drug substitution; drug withdrawal; electron microscopy; follow up; hepatitis B; hospitalization; human; human tissue; immunoblotting; immunosuppressive treatment; injection; Kaposi sarcoma; liver function test; lymphocytopenia; male; serology; skin biopsyjournal article2-s2.0-45549093471